Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Simultaneous Scalp, Skull, Kidney, and Pancreas Transplant from a Single Donor

Selber, Jesse C., M.D., M.P.H.; Chang, Edward I., M.D.; Clemens, Mark W., M.D.; Gaber, Lilian, M.D.; Hanasono, Matthew M., M.D.; Klebuc, Michael, M.D.; Skoracki, Roman J., M.D.; Trask, Todd, M.D.; Yu, Peirong, M.D.; Gaber, A. Osama, M.D.

Plastic and Reconstructive Surgery: June 2016 - Volume 137 - Issue 6 - p 1851-1861
doi: 10.1097/PRS.0000000000002153
Reconstructive: Head and Neck: Original Articles
Press Release
Watch Video

Background: Vascularized composite allotransplantation is an emerging field, but the complications of lifelong immunosuppression limit indications. Vascularized composite allotransplantation in solid organ recipients represents a unique opportunity because immunosuppression has already been accepted. This report of a simultaneous scalp, skull, kidney, and pancreas transplant represents both the first skull-scalp transplant and combination of a vascularized composite allotransplantation with double organ transplantation.

Methods: A previous recipient of a kidney-pancreas transplant presented with osteoradionecrosis of the calvaria and a large area of unstable scalp following successful, curative treatment of a scalp tumor. His kidney and pancreas functions were also critically poor. A multidisciplinary, multi-institutional plan was developed to perform a simultaneous scalp, skull, and repeated kidney and pancreas transplantation, all from a single donor.

Results: Eighteen months after the patient was listed with the United Network for Organ Sharing, a donor was identified and the multiorgan vascularized composite allotransplantation was performed. Twenty physicians and 15 hours were required to perform donor and recipient procedures. The patient recovered well and was discharged on postoperative day 15. He has had one episode of scalp rejection confirmed by biopsy and treated successfully. His creatinine value is currently 0.8 mg/dl, from 5.0 mg/dl, and his blood glucose levels are normal without supplemental insulin. Aesthetic outcome is very satisfactory. The patient is now 1 year post-transplantation and doing well.

Conclusions: Vascularized composite allotransplantation in solid organ recipients is an expansion of current indications to already immunosuppressed patients. Rejection of the vascularized composite allotransplant without solid organ rejection can occur and is treatable. Methodical planning, an interdisciplinary approach, and careful management of all organs are critical to success.


Houston, Texas

From the Department of Plastic Surgery, The University of Texas M. D. Anderson Cancer Center; and the Departments of Surgery, Plastic Surgery, and Neurosurgery and the J.C. Walter Jr. Transplant Center, Houston Methodist Hospital.

Received for publication October 14, 2015; accepted January 13, 2016.

Presented at the Medical Innovations Summit, Royal Society of Medicine, in London, England, September 12, 2015.

Disclosure:The authors have no conflict of interest related to the content of this article.

Supplemental digital content is available for this article. Direct URL citations appear in the text; simply type the URL address into any Web browser to access this content. Clickable links to the material are provided in the HTML text of this article on the Journal’s Web site (

A “Hot Topic Video” by Editor-in-Chief Rod J. Rohrich, M.D., accompanies this article. Go to and click on “Plastic Surgery Hot Topics” in the “Videos” tab to watch. On the iPad, tap on the Hot Topics icon.

Jesse C. Selber, M.D., M.P.H., Department of Plastic Surgery, The University of Texas M. D. Anderson Cancer Center, 1400 Pressler Street, Unit 1488, Houston, Texas 77030

Copyright © 2016 by the American Society of Plastic Surgeons